Table 29: Impact of eTools on Other Outcomes of Appropriately Managed Medications.
| Author, Year | Study Design | Length of Follow-up | Sample Size, n (Intervention/Control) | Results, % (Intervention/Control) | Effect Estimate (95% CI) |
|---|---|---|---|---|---|
| Walsh et al, 2012 (41) | Observational | 24 months | 4,220/2,950 |
Aldosterone antagonist 17.4/20.7 |
aORa 0.86 (0.49–1.50) |
| Walsh et al, 2012 (41) | Observational | 24 months | 4,220/2,950 |
ICD/CRT-D 19.1/18.0 |
aORa 1.06 (0.78–1.44) |
| Walsh et al, 2012 (41) | Observational | 24 months | 4,220/2,950 |
Beta-blocker 6.9/5.3 |
aORa 1.43 (1.05–1.93) |
| Walsh et al, 2012 (41) | Observational | 24 months | 4,220/2,950 |
CRT-P/CRT-D 33.6/31.1 |
aORa 1.33 (0.73–2.43) |
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; CRT-D, cardio-resynchronization therapy with defibrillator; CRT-P, cardio-resynchronization therapy with pacemaker; eTool, electronic tool; ICD, implantable cardioverter defibrillator.
a
Adjusted for patient and practice characteristics.